Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $362,246.40 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Friday, February 14th, Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $6.45 during mid-day trading on Tuesday, reaching $250.00. 910,244 shares of the company were exchanged, compared to its average volume of 691,530. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock has a market capitalization of $32.25 billion, a PE ratio of -95.42 and a beta of 0.35. The company’s 50 day moving average price is $254.04 and its 200 day moving average price is $263.44.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALNY. Scotiabank decreased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Sanford C. Bernstein cut their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. TD Cowen raised their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. Larson Financial Group LLC raised its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the period. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $29,000. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth $33,000. Finally, OFI Invest Asset Management purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth $35,000. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.